Systematic review: Combination therapies for treatment-naïve chronic hepatitis B

Alimentary Pharmacology and Therapeutics

Volumn 27, Issue 12, 2008, Pages 1187-1209

  Kumar, M ^a   Sarin, S K ^a,b  

^a UNIVERSITY OF DELHI   (India)

^b G B PANT HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; CLEVUDINE; ELVUCITABINE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 12; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PENCICLOVIR; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; TELBIVUDINE; THYMOSIN; VACCINE; VIRUS DNA;

ADD ON THERAPY; ANTIVIRAL RESISTANCE; CHRONIC HEPATITIS; DRUG EFFICACY; HEPATITIS B; HUMAN; IMMUNOMODULATION; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; SYSTEMATIC REVIEW; VIRUS INHIBITION; VIRUS MUTATION;

ANTIVIRAL AGENTS; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; INTERLEUKINS; MALE; NUCLEOTIDES; OUTCOME ASSESSMENT (HEALTH CARE); RNA, SMALL INTERFERING; VIRAL LOAD;

EID: 43849097049     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03695.x     Document Type: Review

References (94)

1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003 362 : 2089 94.
2. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003 37 : 748 55.
3. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000 32 : 803 6.
4. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006 44 : 593 606.
5. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007 45 : 507 39.
6. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003 124 : 105 17.
7. Richman DD. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology 2000 32 : 866 7.
8. Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007 132 : 1574 85.
9. Locarnini S. Hepatitis B viral resistance: mechanisms and diagnosis. J Hepatol 2003 39 : S124 32.
10. Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007 46 : 1695 703.
11. Lai CL, Gane E, Liaw YF, Hsu CW, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007 357 : 2576 88.
12. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006 131 : 1743 51.
13. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007 5 : 890 7.
14. Han S, Chang TT, Chao YC, et al. Four-year entecavir treatment in nucleoside-naive HbeAg+ patients: results from studies ETV-022 and -901. Hepatology 2007 46 : 654A.
15. Marcellin P, Buti M, Krastev Z, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): study GS-US-174-0102. American Association for the Study of Liver Diseases, 58th Annual Meeting, 2007: late breaking abstract 2. Hepatology 2007 46 : 290A.
16. Heathcote EJ, Gane E, DeMan R, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): study GS-US-174-0103. American Association for the Study of Liver Diseases, 58th Annual Meeting, 2007: late breaking abstract 6. Hepatology 2007 46 : 861A.
17. Gish R, Chang TT, Lai CL, et al. Hepatitis B surface antigen loss in antiviral-treated patients with HBeAg-positive chronic hepatitis B infection: observations from antiviral-naïve patients treated with entecavir or lamivudine. 57th Annual Meeting of the American Association for the Study of Liver Diseases, 2006. Hepatology 2006 44 : 558A.
18. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004 64 : 1 15.
19. Zoulim F, Dannaoui E, Borel C, et al. 20,30-Dideoxy-beta-L-5- fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob Agents Chemother 1996 40 : 448 53
20. Delaney WEt, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006 50 : 2471 7.
21. Seigneres B, Aguesse-Germon S, Pichoud C, et al. Duck hepatitis B virus polymerasegene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo. J Hepatol 2001 34 : 114 22.
22. Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998 42 : 3200 8.
23. Standring DN, Bridges EG, Placidi L, et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 2001 12 : 119 29.
24. Colledge D, Civitico G, Locarnini S, et al. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob Agents Chemother 2000 44 : 551 60.
25. Delaney WE IV., Yang H, Miller MD, et al. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother 2004 48 : 3702 10.
26. Jacquard AC, Nassal M, Pichoud C, et al. Effect ofa combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother 2004 48 : 2683 92.
27. Lau GKK, Tsiang M, Hou J, et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B infected Chinese: a viral dynamics study. Hepatology 2000 32 : 394 9.
28. Lai CL, Leung N, Teo EK, et al. Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005 129 : 528 36.
29. Lim SG, Krastev Z, Ng TM, et al. Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob Agents Chemother 2006 50 : 1642 8.
30. Sung JJY, Lau JY, Zeuzem S, et al. A randomised double-blind phase II study of lamivudine 435 (LAM) compared to lamivudine and adefovir for treatment-naive patients with chronic hepatitis B (CHB): week 52 analysis. J Hepatol 2003 38 : 25 6.
31. Sung JJY, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008 48 : 728 35.
32. Hui CK, Zhang HY, Bowden S, et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine versus adefovir dipivoxil monotherapy in the treat- ment of chronic hepatitis B. J Hepatol 2008 48 : 714 20.
33. Lim SG, Ng TM, Kung N, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006 166 : 49 56.
34. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004 350 : 1023 35.
35. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg- negative patients developing genotypic resistance to lamivudine. Hepatology 2005 42 : 1414 9.
36. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003 36 : 687 96.
37. Litwin S, Toll E, Jilbert AR, Mason WS. The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations. J Clin Virol 2005 34 : S96 107.
38. Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001 33 : 963 71.
39. Cooksley H, Hou J, Vitek L, et al. Impact of nucleoside treatment on antiviral T-cell reactivity in chronic hepatitis B: major differences depending on early viral suppression, HBeAg status and HBV genotype. Program and abstracts of the 57th Annual Meeting of the American Association for the Study of Liver Diseases, 27-31 October, 2006, Boston, Massachusetts (abstract 967).
40. Sarin SK, Sood A, Kumar M, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007 102 : 96 104.
41. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis Be antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001 33 : 1527 32.
42. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000 46 : 562 8.
43. Barbaro G, Zechini F, Pellicelli AM, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol 2001 35 : 406 11.
44. Yalcin K, Degertekin H, Yildiz F, Celik Y. Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B. Clin Infect Dis 2003 36 : 1516 22.
45. Hasan F, al-Khaldi J, Asker H, et al. Treatment of chronic hepatitis B with the sequential administration of interferon and lamivudine. Hepatogastroenterology 2003 50 : 2040 2.
46. Deng H, Zhao ZX, Xu QH, Zhou YP, Chen YM, Yao JL. Therapy effect of lamivudine combination with alpha interferon on patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2003 11 : 305 8.
47. Sarin SK, Kumar M, Kumar R, et al. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol 2005 100 : 2463 71.
48. Ayaz C, Celen MK, Colak H, Hosoglu S, Geyik MF. Comparison of lamivudine and alpha-interferon combination with alpha-interferon alone in the treatment of HBeAg-positive chronic hepatitis B. Indian J Gastroenterol 2006 25 : 71 3.
49. Asik Akman S, Cokceken Okcu S, Anil OH, Kose S, Bakiler AR. Preliminary results of interferon alpha-2a and lamivudine combination therapy regimen in children with chronic hepatitis B. Mikrobiyol Bul 2006 40 : 47 53.
50. Kansu A, Doganci T, Akman SA, et al. Comparison of two different regimens of combined interferon-alpha2a and lamivudine therapy in children with chronic hepatitis B infection. Antivir Ther 2006 11 : 255 61.
51. Dikici B, Bosnak M, Bosnak V, et al. Combination therapy for children with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2002 17 : 1087 91.
52. Dikici B, Bosnak M, Kara IH, et al. Lamivudine and interferon-alpha combination treatment of childhood patients with chronic hepatitis B infection. Pediatr Infect Dis J 2001 20 : 988 92.
53. Dikici B, Bosnak M, Bosnak V, et al. Comparison of treatments of chronic hepatitis B in children with lamivudine and alpha-interferon combination and alpha-interferon alone. Pediatr Int 2002 44 : 517 21.
54. Ozgenc F, Dikici B, Targan S, et al. Comparison of antiviral effect of lamivudine with interferon-alpha2a versus -alpha2b in children with chronic hepatitis B infection. Antivir Ther 2004 9 : 23 6.
55. Akman SA, Okcu SC, Halicioǧlu O, et al. Therapeutic efficacy of sequential and simultaneous treatments with interferon-alpha and lamivudine in children with chronic hepatitis B. Pediatr Int 2007 49 : 848 52.
56. Kuloglu Z, Krsaçloglu CT, Kansu A, Erden E, Girgin N. Liver histology of children with chronic hepatitis treated with interferon-alpha alone or in combination with lamivudine. J Pediatr Gastroenterol Nutr 2007 45 : 564 8.
57. Yilmaz A, Akcam M, Gelen T, Artan R. Lamivudine and high-dose interferon alpha 2a combination treatment in naïve HBeAg-positive immunoactive chronic hepatitis B in children: an East Mediterranean center's experience. Eur J Pediatr 2007 166 : 195 9.
58. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005 352 : 2682 95.
59. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005 365 : 123 9.
60. Chan HLY, Hui AY, Wong VW, Chim AM, Wong ML, Sung JJ. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 2005 41 : 1357 64.
61. Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005 142 : 240 50.
62. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004 39 : 804 10.
63. Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during peg-interferon {alpha}-2b therapy Gut 2005 54 : 1604 9.
64. van Zonneveld M, Zondervan PE, Cakaloglu Y, et al. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int 2006 26 : 399 405.
65. Manesis EK, Papatheodoridis GV, Hadziyannis SJ. A partially overlapping treatment course with lamivudine and interferon in hepatitis Be antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2006 23 : 99 106.
66. Tatulli I, Francavilla R, Rizzo GL, et al. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol 2001 35 : 805 10.
67. Economou M, Manolakopoulos S, Trikalinos TA, et al. Epameinondas V Tsianos Interferon-α plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J Gastroenterol 2005 11 : 5882 7.
68. Yurdaydin C, Bozkaya H, Cetinkaya H, et al. Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B. J Viral Hepat 2005 12 : 262 8.
69. Santantonio T, Niro GA, Sinisi E, et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002 36 : 799 804.
70. Karabay O, Tamer A, Tahtaci M, Vardi S, Celebi H. Effectiveness of lamivudine and interferon-α combination therapy versus interferon-α monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial. J Microbiol Immunol Infect 2005 38 : 262 6.
71. Nikolaidis NL, Giouleme OI, Tziomalos KA, et al. Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients. J Gastroenterol Hepatol 2005 20 : 1721 5.
72. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004 351 : 1206 17.
73. Kaymakoglu S, Oguz D, Gur G, et al. Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. Antimicrob Agents Chemother 2007 51 : 3020 2.
74. Vassiliadis T, Tziomalos K, Patsiaoura K, et al. Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. J Gastroenterol Hepatol 2007 22 : 1582 8.
75. Rudin D, Shah SM, Kiss A, Wetz RV, Sottile VM. Interferon and lamivudine vs. interferon for hepatitis Be antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials. Liver Int 2007 27 : 1185 93.
76. Ruden D. Lamivudine and interferon versus lamivudine monotherapy for HBeAg-positive hepatitis B treatment: a meta-analysis of randomized, controlled trials. Adv Ther 2007 24 : 784 95.
77. Jang MK, Chung YH, Choi MH, et al. Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy. J Gastroenterol Hepatol 2004 19 : 1363 8.
78. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006 44 : 675 84.
79. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005 5 : 215 29.
80. Chisari FV. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 2000 156 : 1117 32.
81. Naoumov NV, Rossol S. Studies of interleukin-12 in chronic hepatitis B virus infection. J Viral Hepat 1997 4 (Suppl. 2 87 91.
82. Cavanaugh VJ, Guidotti LG, Chisari FV. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol 1997 71 : 3236 43.
83. Lohr HF, Pingel S, Bocher WO, et al. Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B: restoration by exogenous interleukin-12. Clin Exp Immunol 2002 130 : 107 14.
84. Rigopoulou EI, Suri D, Chokshi S, et al. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology 2005 42 : 1028 36.
85. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998 339 : 1493 9.
86. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998 339 : 1485 92.
87. Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003 37 : 568 76.
88. Liu CJ, Chen PJ, Chen DS. A forgotten population with chronic hepatitis C infection: subjects coinfected with hepatitis B virus. Hepatology 2004 40 : 266.
89. Ren FY, Jin H, Piao XX, Piao FS. Ribavirin and IFN-alpha combination therapy induces CD4 + T-cell proliferation and Th1 cytokine secretion in patients with chronic hepatitis B. World J Gastroenterol 2007 13 : 5440 5.
90. Liu CJ, Lai MY, Chao YC, et al. Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study. Hepatology 2006 43 : 742 9.
91. Lei CL, Peng XM, Tang XP, Yang Z, Fan HM, Yuan XZ. Clinical trial of sequential antiviral therapy for patients with chronic hepatitis B in China. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2004 18 : 69 72.
92. Chen Z, Xu ZF, Ye JJ, Yao HP, Zheng S, Ding JY. Combination of small interfering RNAs mediates greater inhibition of human hepatitis B virus replication and antigen expression. J Zhejiang Univ Sci 2005 6 : 236 41.
93. Lim SG, Wai CT, Lee YM, et al. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther 2006 11 : 245 53.
94. Helvaci M, Kizilgunesler A, Kasirga E, Ozbal E, Kuzu M, Sozen G. Efficacy of hepatitis B vaccination and interferon-alpha-2b combination therapy versus interferon-alpha-2b monotherapy in children with chronic hepatitis B. J Gastroenterol Hepatol 2004 19 : 785 91.